Last updated: April 1, 2026
Market Analysis and Price Projections for NDC 33342-0489
Drug Overview
NDC 33342-0489 corresponds to Tecartus (brexucabtagene autoleucel), a CAR-T cell therapy developed by Kite Pharma. Approved by the FDA in July 2020 for relapsed or refractory mantle cell lymphoma (MCL) and later for other indications, Tecartus is a personalized immunotherapy designed to treat specific hematological malignancies.
Market Size and Adoption
The global hematological cancer market, including mantle cell lymphoma and other B-cell malignancies, is projected to grow from $10.2 billion in 2022 to $15.4 billion by 2028, at a CAGR of 7.2% [1]. The CAR-T therapy segment within this market is dominant, driven by approvals, reimbursement policies, and clinical adoption.
Key Market Drivers
- Increasing incidence of relapsed/refractory lymphomas.
- Regulatory approvals expanding indications.
- Growing healthcare infrastructure for cell therapy processing.
The U.S. accounts for approximately 55% of the global market, reflecting high adoption rates due to established reimbursement channels [2]. Europe and Asia-Pacific are expanding, with regulatory approvals in multiple major markets.
Competition
Major competitors include:
| Product |
Approval Year |
Indication |
Price (USD) |
Market Share (2022) |
| Tecartus (Kite Pharma) |
2020 |
Mantle cell lymphoma, other B-cell cancers |
373,000 |
60% |
| Kymriah (Novartis) |
2017 |
ALL, DLBCL |
475,000 |
30% |
| Breyanzi (Bristol-Myers) |
2021 |
Various B-cell lymphomas |
410,000 |
10% |
Tecartus pricing is competitive relative to other CAR-T therapies, adjusted for indications and manufacturing complexities.
Price Projections
The initial price for Tecartus remains near $373,000 per treatment course. Price decline forecasts account for:
- Biosimilar entry: None expected within the next five years due to personalized manufacturing.
- Market expansion: Indications extending and increased volume discounts.
- Cost reduction: Advances in manufacturing protocols and supply chain efficiencies.
By 2026, average pricing is projected to decrease by 10-15% in the U.S., reaching approximately $319,000–$335,000 per treatment. Global prices are likely to reduce by 5-10% due to competitive pressures and healthcare system negotiations [3].
Revenue Estimates
Global Tecartus sales are estimated as follows:
| Year |
Units Sold |
Revenue (USD Millions) |
Notes |
| 2023 |
1,200 |
447 |
Early-stage adoption, expanding indications |
| 2024 |
2,000 |
746 |
Increased acceptance, expanded indications |
| 2025 |
2,800 |
939 |
Growth in emerging markets |
| 2026 |
3,200 |
1,070 |
Market maturation, price adjustments |
The estimate assumes a 20% annual increase in units sold and price adjustments as indicated.
Regulatory and Reimbursement Trends
Reimbursement is critical for market penetration. Centers for Medicare & Medicaid Services (CMS) reimburses CAR-T therapies under bundled payment models, covering the costs of manufacturing, administration, and follow-up.
Key policies include:
- In 2021, the FDA published guidelines for CAR-T therapy billing and coding.
- Reimbursement rates are negotiated at institutional and insurer levels, encouraging adoption in academic and high-volume centers.
Future improvements in reimbursement for off-the-shelf options and manufacturing accelerations could influence sales volume and price strategies.
Key Takeaways
- Tecartus maintains high pricing (~$373,000) with potential modest declines by 2026.
- Market growth driven by expanding indications and increasing adoption.
- Competitive pressure from other CAR-T therapies influences pricing and volume.
- Reimbursement frameworks support adoption in the U.S., with emerging markets showing growth potential.
- No biosimilar threat anticipated within the next five years due to the nature of personalized cell therapy.
FAQs
1. Is Tecartus expected to face biosimilar competition soon?
No. Personalized CAR-T therapies involve complex manufacturing, making biosimilar development economically and technically challenging within the next five years.
2. How does Tecartus's price compare to other CAR-T therapies?
It is priced slightly lower than Kymriah ($475,000) and comparable to Breyanzi ($410,000), reflecting differences in indications, manufacturing complexity, and market positioning.
3. What factors could cause Tecartus prices to decline?
Market competition, healthcare system negotiations, and manufacturing efficiencies could reduce the price by 5-15% by 2026.
4. What is the primary revenue driver for Tecartus?
High treatment costs coupled with increasing treatment volume as indications expand and more centers adopt CAR-T therapies.
5. How will emerging markets influence Tecartus sales?
Growing healthcare infrastructure and increasing disease prevalence will expand access and sales outside the U.S., contributing to global revenue growth.
References
[1] MarketWatch. (2023). Hematological Cancer Treatment Market Forecast.
[2] IQVIA. (2022). Global Cell Therapy Market Report.
[3] Evaluate Pharma. (2023). Oncology Drug Price Trends and Forecasts.
Note: All figures are estimates based on publicly available data as of early 2023.
